drugset / Trial / NCT02756650
1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement
NaSingle-groupOpen-labelTreatment
Summary
Primary objective of the study was to evaluate the safety and efficacy of canakinumab on the clinical and inflammatory findings of Behced Disease patients with neurologic and vascular involvement.
Timeline
- Start
- 2016-06-23
- Primary completion
- 2019-01-31
- Completion
- 2019-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Canakinumab | Monoclonal antibody | 150 mg | Intravenous |
| Subject | Canakinumab | Monoclonal antibody | 300 mg | Intravenous |